Merck and Pfizer are to take on the crowded SGLT2 inhibitor market with a keenly-priced new contender. The FDA approved Steglatro (ertugliflozin) as a monotherapy in conjunction with diet and exercise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback